DVM

ATCC Announces Award from NIAID to Provide Antiviral Screening Assays Relevant to Human Diseases

Retrieved on: 
onsdag, maj 29, 2024
Infectious Diseases, Biotechnology, Health, Clinical Trials, Human services, Bangladesh Technical Education Board, Doctor of Philosophy, NIAID, Infection, COVID-19, Instability, WCCM, National Institutes of Health, Engineering, MBA, Senior, DVM, Government, BSL, Virus, NIH, Vaccine

Under this task order 75N93019D00002-75N93024F00001, ATCC will develop well-characterized challenge material (WCCM) for the In Vitro Assessment for Antimicrobial Activity (IVAAA) program.

Key Points: 
  • Under this task order 75N93019D00002-75N93024F00001, ATCC will develop well-characterized challenge material (WCCM) for the In Vitro Assessment for Antimicrobial Activity (IVAAA) program.
  • This program aims to evaluate candidate countermeasures against microbial pathogens and vectors, including those derived from clinical specimens.
  • The assessments are conducted in vitro and focus on antiviral screening assays for biosafety level (BSL)-3/4 viruses relevant to human diseases, as well as other rapidly emerging viruses that employ similar assay methodologies.
  • Ensuring the genomic homogeneity of WCCM, as well as improving the production capacity of WCCM used in drug screening studies, is essential for therapeutic drug development.

Introducing Arista Advanced Pet Care: Revolutionizing Specialty & Emergency Veterinary Medicine with a Shared Ownership Model

Retrieved on: 
tisdag, maj 28, 2024
Health, Veterinary, Pets, Consumer, Veterinary medicine, Hospital, Practitioner, Veterinarian, DVM, Movement, Pet, General practice, Multimedia

Arista Advanced Pet Care, a groundbreaking venture led by veterinarian Jennifer Welser, DVM, DACVO, is set to redefine the landscape of specialty & emergency pet care with its innovative shared ownership model.

Key Points: 
  • Arista Advanced Pet Care, a groundbreaking venture led by veterinarian Jennifer Welser, DVM, DACVO, is set to redefine the landscape of specialty & emergency pet care with its innovative shared ownership model.
  • View the full release here: https://www.businesswire.com/news/home/20240528935882/en/
    Arista Advanced Pet Care, a groundbreaking venture led by veterinarian Jennifer Welser, DVM, DACVO, is set to redefine the landscape of specialty & emergency pet care with its innovative shared ownership model.
  • What sets Arista apart is its unique shared ownership model and its commitment to providing seamless and transparent advanced pet care.
  • "At Arista Advanced Pet Care, we are committed to revolutionizing veterinary medicine by putting control back into the hands of our dedicated veterinary teams," says Dr. Welser, President of Arista Advanced Pet Care.

Does Your Dog Need Glasses? From Removing Cataracts and Performing Surgeries to Restore Vision, Veterinarians and Veterinary Nurses/Technicians Master Ophthalmology and Other New Skills at the 23rd NAVC Institute

Retrieved on: 
måndag, maj 13, 2024
Patient, Learning, Ohio State University, Irritation, Veterinary medicine, Practitioner, Education, University, Veterinarian, Trauma, Cataract, Glaucoma, Rabbit, Cat, Snake, Animal, College, Horse, DVM, Eye, Pet, Associate, Eyelid, Dog, Knowledge

The unique program enables veterinary professionals to master new skills they can immediately put into practice.

Key Points: 
  • The unique program enables veterinary professionals to master new skills they can immediately put into practice.
  • In addition to ophthalmology, NAVC Institute provides in-depth education tracks on orthopedic surgery, small animal ultrasound, soft tissue surgery and strategic leadership for veterinary practice managers.
  • The hands-on training and skills veterinarians and veterinary nurses/technicians gain at NAVC Institute, whether it's in ophthalmology or orthopedic surgery, enable general practitioners to treat their patients, providing more immediate easily-accessible care."
  • With this intensive area of focus and new skills, veterinary professionals can provide greater care to their patients.

Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Health, Clinical Trials, AMD, Ophthalmology, City, Regenerative medicine, Research, Spinal cord, NanoString Technologies, Roche, MD, Doctor of Philosophy, Partnership, Conference, Trial of the century, Webcast, Corporate development, Beckman Research Institute, CIRM, DVM, Patient, Lineage, Geographic atrophy, Madrona Venture Group, Expense, RPE, Therapy, Delivery, G&A, Partner, Interest, Fine chemical

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its first quarter 2024 financial and operating results and will host a conference call at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.
  • “The quarter was highlighted by significant milestones and data updates on our lead program,” stated Brian M. Culley, Lineage CEO.
  • Under this new agreement, Lineage will provide additional clinical, technical, training and manufacturing services that further support the ongoing advancement and optimization of the OpRegen program.
  • Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

Retrieved on: 
fredag, maj 10, 2024
Infection, Vaccination, University, Pelvic inflammatory disease, Bangladesh Technical Education Board, Molecular genetics, Rutgers University, Zhong, Mouse, Chlamydia, Food, Tissue, Infertility, Texas Biomedical Research Institute, University of Texas System, Doctor of Philosophy, Research, Vaccine, IND, NIAID, Disease, GI, Investigational New Drug, Gastrointestinal tract, DVM, Microbiology, MPH, Immunology, Vertically transmitted infection, HPV, Workforce, Hepatitis B, SAN, Hepatitis A

SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.

Key Points: 
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most reported sexually transmitted disease, with funding from the National Institutes of Health.
  • SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.
  • The UT Health San Antonio-led study of a novel oral vaccine that could protect against chlamydia infection is being funded through a cooperative agreements research project grant, known as a U01 grant.
  • Back in 2022, UT Health San Antonio was granted an exclusive global license to allow Ohio biopharmaceutical company Blue Water Vaccines Inc. to develop Zhong's findings into an oral vaccine for chlamydia.

Multi Radiance Medical Renews Long-Term Global Sponsorship With ISELP

Retrieved on: 
torsdag, maj 9, 2024
Veterinary, Other Manufacturing, Medical Devices, Pets, Health Technology, Manufacturing, Biotechnology, General Health, Consumer, Health, Relaxation, FDA, International Society, Veterinarian, Partnership, Light, Limp, DVM, Laser, Anaphylaxis, FEI, Horse, Medical imaging

Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .

Key Points: 
  • Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .
  • “As a leader in equine laser therapy, it is only fitting that we continue to partner with the highest level of equine veterinarians, and ISELP represents just that,” says Max Kanarsky, President and CEO of Multi Radiance Medical.
  • Kent Allen, DVM, ISELP board member and chair of the USEF Drugs and Medications Committee and Veterinarian Committee, says, "Science-based adjunctive treatments provide alternatives that help reduce drug-related side effects, making Multi Radiance an ideal partner."
  • I’m seeing reduced healing times, and improvements in healing in some cases unresponsive to a conventional approach.”
    To learn more about Multi Radiance and WellVu visit: https://info.multiradiance.com/vet/mrv_iselp

HILL'S PET NUTRITION LAUNCHES SHOP.HILLSPET.COM AND NEW DONATION PROGRAM TO SUPPORT ANIMAL SHELTERS

Retrieved on: 
onsdag, maj 8, 2024
Organization, Pet, Food, Marketing, Science Diet, Shelter, Parent, Cat, Colgate-Palmolive, Senior, DVM, Hill's Pet Nutrition, Dog, MBA, Hill

OVERLAND PARK, Kan., May 8, 2024 /PRNewswire/ -- Hill's Pet Nutrition (Hill's), a division of Colgate-Palmolive and a global leader in science-led nutrition, today announced the launch of its new shopping platform, shop.hillspet.com and a new donations program that will benefit shelter partners of the Hill's Food, Shelter & Love program, as well as leading animal welfare organizations like Greater Good Charities. For every purchase of Hill's Science Diet through the new site, Hill's will donate $1 to a participating animal shelter of the shopper's choosing.

Key Points: 
  • Customers have the option to add their own donation amount to further support the participating shelter of their choosing.
  • One hundred percent of all donations go directly to shelters to support their life-changing work helping homeless pets in need.
  • "Every donation will support the hardworking shelter partners who are a part of the Hill's Food, Shelter & Love program."
  • "With shop.hillspet.com , we are excited that something as simple as a regular purchase of pet food will directly benefit a shelter pet."

Registration Now Open for 'A Different Way to CE!'

Retrieved on: 
fredag, maj 3, 2024
Family, DVM, Student, Conference, Learning, Knowledge, Meal, Convention center, CE

LANCASTER, S.C., May 3, 2024 /PRNewswire/ -- 'A Different Way to CE' is back for the fourth year in Nashville, Tennessee! The annual continuing education veterinary conference, sponsored by Nutramax Laboratories Veterinary Sciences, Inc., welcomes veterinary professionals and students from around the world to the Gaylord Opryland Resort & Convention Center. Attendees will enjoy one-of-a-kind fellowship with other veterinary professionals, superior entertainment, and opportunities to stretch their knowledge with educational sessions designed just for them! 

Key Points: 
  • LANCASTER, S.C., May 3, 2024 /PRNewswire/ -- 'A Different Way to CE' is back for the fourth year in Nashville, Tennessee!
  • The annual continuing education veterinary conference, sponsored by Nutramax Laboratories Veterinary Sciences, Inc ., welcomes veterinary professionals and students from around the world to the Gaylord Opryland Resort & Convention Center.
  • Attendees will enjoy one-of-a-kind fellowship with other veterinary professionals, superior entertainment, and opportunities to stretch their knowledge with educational sessions designed just for them!
  • Interested veterinary professionals and students can click here to sign up for 'A Different Way to CE' 2024!

VCA Animal Hospital's Todd Lavender, DVM, Transitions to Role as Chief Transformation Officer for Mars Veterinary Health as Patty Wu Joins as New VCA President

Retrieved on: 
torsdag, maj 2, 2024
Clorox, Walmart, Hospital, Beautycounter, Pet, EVP, Health, VCA, Veterinary medicine, The Honest Company, DVM, VCA Animal Hospitals, Patient, Bed Bath & Beyond, BABY, LOS, Buy Buy Baby, Pleasure, Associate, Growth, CPG, Nursing

LOS ANGELES, May 2, 2024 /PRNewswire/ -- VCA Animal Hospitals, the global leader of comprehensive veterinary services and proudly part of Mars Veterinary Health, today announced the appointment of Patty Wu as president, effective May 2024. Patty succeeds Todd Lavender, DVM, who, following a successful 20 years at VCA, will become Chief Transformation Officer of Mars Veterinary Health.

Key Points: 
  • Patty succeeds Todd Lavender, DVM, who, following a successful 20 years at VCA, will become Chief Transformation Officer of Mars Veterinary Health.
  • Lavender for many years, and throughout this time, he's encouraged our teams to lead in medical quality, spread the joy of our profession and innovate for our clients," said Doug Drew, president, Mars Veterinary Health.
  • Drew continued: "I'm thrilled to welcome Patty to VCA and the Mars Veterinary Health family.
  • Patty commented: "Over the past few years, VCA has expanded access to care, experienced amazing growth and stayed true to an Associate-first, pet-centric culture.

Veranex Acquires Leading Pathology and Histology Provider HORUS Scientific

Retrieved on: 
onsdag, maj 1, 2024
Pathology, Growth, Engineering, DVM, GLP, Acquisition, Histology, Good laboratory practice, Knowledge

RALEIGH, N.C., May 1, 2024 /PRNewswire/ -- Veranex, the first purpose-built, integrated global service platform for the medtech industry, announced that it has acquired HORUS Scientific, a pathology and histology facility. This acquisition further solidifies Veranex's global commitment by deepening its end-to-end service capabilities for medtech innovation.

Key Points: 
  • "The growth of Veranex is a direct result of unwavering commitment to our clients' success," said Pat Donnelly, Chairman and CEO of Veranex.
  • "By joining forces with HORUS Scientific, we are not only expanding our footprint but enriching our collective expertise, strengthening our histology service capabilities, and enhancing the value we bring to our clients and partners."
  • "HORUS is excited to join the Veranex team — an organization with an outstanding reputation," said Dr. Stanley.
  • The additional capability added in North America will complement Paris's globally integrated in-house pathology and histology services, strengthening Veranex's overall pathology service line.